AstraZeneca plc (AZN) Stock Rating Reaffirmed by Credit Suisse Group AG
AstraZeneca plc (LON:AZN)‘s stock had its “underperform” rating reiterated by equities research analysts at Credit Suisse Group AG in a report issued on Friday. They currently have a GBX 4,000 ($52.21) price objective on the biopharmaceutical company’s stock. Credit Suisse Group AG’s price objective suggests a potential downside of 21.35% from the stock’s current price.
A number of other equities analysts have also weighed in on AZN. Jefferies Group upped their price objective on AstraZeneca plc from GBX 3,900 ($50.91) to GBX 4,100 ($53.52) and gave the stock a “hold” rating in a research note on Tuesday, June 14th. BNP Paribas lowered AstraZeneca plc to a “neutral” rating and set a GBX 5,200 ($67.88) price target for the company. in a research note on Wednesday, September 14th. HSBC reissued a “hold” rating and set a GBX 4,700 ($61.35) price target on shares of AstraZeneca plc in a research note on Thursday, August 11th. Beaufort Securities reissued a “hold” rating on shares of AstraZeneca plc in a research note on Wednesday, August 10th. Finally, Societe Generale set a GBX 7,000 ($91.37) price target on AstraZeneca plc and gave the company a “buy” rating in a research note on Thursday, September 8th. Five investment analysts have rated the stock with a sell rating, fourteen have issued a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Hold” and an average price target of GBX 4,937.91 ($64.46).
AstraZeneca plc (LON:AZN) traded up 1.19% during trading on Friday, hitting GBX 5086.00. The stock had a trading volume of 3,384,720 shares. The stock’s market cap is GBX 64.34 billion. The stock has a 50 day moving average price of GBX 5,005.11 and a 200-day moving average price of GBX 4,435.88. AstraZeneca plc has a 12 month low of GBX 3,680.00 and a 12 month high of GBX 5,505.00.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/07/astrazeneca-plc-azn-stock-rating-reaffirmed-by-credit-suisse-group-ag.html
The business also recently disclosed a dividend, which was paid on Monday, September 12th. Shareholders of record on Thursday, August 11th were paid a dividend of GBX 68.70 ($0.90) per share. The ex-dividend date was Thursday, August 11th. This represents a dividend yield of 1.37%.
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.